ORGO News and Press, Organogenesis Holdings Inc. From 06/30/22

CANTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...

Pharmaceuticals and biotechnology are cheap relative to 11-year valuation averages. Life science tools and healthcare equipment are overvalued. IXJ: a global alternative to XLV. 10 stocks cheaper than their peers in May. For further details see: IXJ: Healthcare Dashb...

Today, we revisit advance wound care name Organogenesis Holdings for the first time since late in 2020. This small cap healthcare concern is already profitable and continues to build out its product portfolio. A full investment analysis follows in the paragraphs below. For f...

Image source: The Motley Fool. Organogenesis Holdings Inc. (NASDAQ: ORGO) Q1 2022 Earnings Call May 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Organogenesis Holdings Inc. (ORGO) Q1 2022 Earnings Call Transc...

Organogenesis Holdings Inc. (ORGO) Q1 2022 Earnings Conference Call May 10, 2022 05:00 PM ET Company Participants Gary Gillheeney - President and Chief Executive Officer David Francisco - Chief Financial Officer Conference Call Participants Danielle Antalffy - SVB Leerink LLC Steven Lichtman ...

Organogenesis Holdings press release (NASDAQ:ORGO): Q1 GAAP EPS of $0.00 misses by $0.05. Revenue of $98.12M (-4.3% Y/Y) beats by $2.4M. Shares -7.41%. For further details see: Organogenesis Holdings GAAP EPS of $0.00 misses by $0.05, revenue of $98.12M beats by $2.4M

CANTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, tod...

CANTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, tod...

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the lates...